Advanced in Large-Cell Immunoblastic Lymphoma

Marjolein M. Van Der Poel-Van Der Gaag

Maastricht, LI, NL 
Advanced in Large-Cell Immunoblastic Lymphoma
Maastricht, LI, NL 
OverviewLocationsClinical Research

Overview

Marjolein Van Der Poel-Van Der Gaag practices in Maastricht, Netherlands. Van Der Poel-Van Der Gaag is rated as an Advanced expert by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. Their top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 119 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Large-Cell Immunoblastic Lymphoma.

Locations

Maastricht, LI, Netherlands
Other Locations
St. Antonius Hospital
Nieuwegein, UT, Netherlands
Nijmegen, GE, Netherlands
Utrecht, UT, Netherlands
Amsterdam, NH, Netherlands
The Hague, Netherlands
Rotterdam, ZH, Netherlands
Hoofddorp, NH, Netherlands
Wageningen, GE 6700AH, Netherlands
Haag, LI, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2024
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Enrollment Status: Unknown
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Daunorubicin, Cytarabine, Idarubicin, Etoposide
Study Phase: Phase 3
A Survivorship Project to UnerstAnd and to impRove Long-Term Outcomes for Acute Myeloid Leukemia Patients (SPARTA): the Sparta Platform
A Survivorship Project to UnerstAnd and to impRove Long-Term Outcomes for Acute Myeloid Leukemia Patients (SPARTA): the Sparta Platform
Enrollment Status: Unknown
Publish Date: March 04, 2020
Intervention Type: Other
View 3 Less Clinical Trials

119 Total Publications

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Van Der Poel-Van Der Gaag's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile